Michael Fuchs
Overview
Explore the profile of Michael Fuchs including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
332
Citations
6843
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Oertel M, Holscher P, Hering D, Kittel C, Fuchs M, Haverkamp U, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539503
Purpose: Hodgkin lymphoma is a hematologic malignancy with excellent outcomes even in advanced stages. Consequently, the importance of treatment-associated toxicity increases. However, the exact estimation of individualized rates is difficult...
22.
Driessen J, de Wit F, Herrera A, Zinzani P, LaCasce A, Cole P, et al.
Blood Adv
. 2024 Mar;
8(11):2740-2752.
PMID: 38502227
Several single-arm studies have explored the inclusion of brentuximab vedotin (BV) in salvage chemotherapy followed by autologous stem cell transplantation (ASCT) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL). However, no...
23.
Bajaj J, Fagan A, Gavis E, Mousel T, Gallagher M, Puri P, et al.
Hepatol Commun
. 2024 Feb;
8(2).
PMID: 38315140
Background: Minimal hepatic encephalopathy (MHE) negatively affects the prognosis of cirrhosis, but treatment is not standard. Rifamycin SV MMX (RiVM) is a nonabsorbable rifampin derivative with colonic action. Methods: In...
24.
Knaup H, Weindler J, van Heek L, Voltin C, Fuchs M, Borchmann P, et al.
Acad Radiol
. 2023 Dec;
31(7):3020-3025.
PMID: 38155023
Rationale And Objectives: In oncological imaging, the use of metabolic tumor volume (MTV) for further prognostic differentiation and the development of risk adapted strategies appears promising. The aim of this...
25.
Fagan A, Gallagher M, Mousel T, Davis B, Fuchs M, Puri P, et al.
Am J Gastroenterol
. 2023 Dec;
119(5):977-981.
PMID: 38153339
Lactulose-based hepatic encephalopathy treatment requires bowel movements/day titration, which is improved with Bristol stool scale (BSS) incorporation. Dieta app evaluates artificial intelligence (AI)-based BSS (AI-BSS) with stool images. Initially, controls...
26.
Caffard T, Awan Malik H, Lutz B, Dobrindt O, Dornacher D, Faschingbauer M, et al.
Eur Spine J
. 2023 Dec;
33(2):752-753.
PMID: 38057590
No abstract available.
27.
Ludwig A, Meuret S, Battmer R, Fuchs M, Ernst A, Schonwiesner M
Audiol Neurootol
. 2023 Dec;
29(3):193-206.
PMID: 38043510
Introduction: Spatial hearing is most accurate using both ears, but accuracy decreases in persons with asymmetrical hearing between ears. In participants with deafness in one ear but normal hearing in...
28.
Jinato T, Sikaroodi M, Fagan A, Sterling R, Lee H, Puri P, et al.
Gut Microbes
. 2023 Nov;
15(2):2288168.
PMID: 38010871
Cognitive dysfunction due to minimal hepatic encephalopathy (MHE) adversely impacts patients with cirrhosis and more precise therapies are needed. Gut-brain axis changes are therapeutic targets, but prior studies have largely...
29.
Younossi Z, Alqahtani S, Alswat K, Yilmaz Y, Keklikkiran C, Funuyet-Salas J, et al.
J Hepatol
. 2023 Nov;
80(3):419-430.
PMID: 37984709
Background & Aims: Patients with fatty liver disease may experience stigma from the disease or comorbidities. In this cross-sectional study, we aimed to understand stigma among patients with nonalcoholic fatty...
30.
Wang Y, Pandak W, Hylemon P, Min H, Min J, Fuchs M, et al.
Am J Physiol Gastrointest Liver Physiol
. 2023 Nov;
326(2):G147-G162.
PMID: 37961761
Cholestenoic acid (CA) has been reported as an important biomarker of many severe diseases, but its physiological and pathological roles remain unclear. This study aimed to investigate the potential role...